In addition, our aim was to assess 1) the proportion of patients with premature CAD and probable/definite FH based on DLCN-criteria; 2) the proportion of patients with probable/definite FH who were tested for the four founder LDLR mutations as recommended in the Finnish national guidelines; 3) the proportion of genetically confirmed FH cases admitted to the cascade screening protocol. The gene discussed is LDLR; the disease is familial hyperaldosteronism.